The Jackson Laboratory, a Bar Harbor-based nonprofit biomedical research institution, has appointed a new president and CEO and said its current head is resigning from his post – but not leaving the organization.
Jackson Lab said in a press release Monday that Lon Cardon, a pioneer in human genetics and drug discovery, would succeed current leader Dr Edison Liu in late November. However, he said Liu will continue his research in the laboratory studying functional cancer genomics with a focus on breast cancer.
Jackson Lab breeds specialized mice for scientific research and is engaged in a variety of research projects related to cancer, tissue regeneration, and other cutting-edge areas of biology and medicine.
“After ten years of leading (the lab) through impressive expansion, dramatic changes and remarkable achievements, Ed (Liu) has made an indelible impact… as a leader, researcher and oncologist in our local communities and in the field. worldwide in biomedical research, ”said David Roux, chairman of the laboratory’s board of directors. “We are now delighted to appoint Lon as the next President and CEO… Under his leadership, Lon will guide the lab through its next period of intense growth. “
Cardon joined California-based pharmaceutical company BioMarin Pharmaceutical in 2017 as Scientific Director and Senior Vice President and was promoted in 2019 to Director of Scientific Strategy.
Prior to joining BioMarin, he was senior vice president of UK pharmaceutical company GlaxoSmithKline, leading departments and divisions spanning genetics, molecular biology, computational biology, statistics and epidemiology.
Prior to Cardon’s 14-year career in the pharmaceutical industry, he spent the first half of his career as a senior scholar in the UK and US, first as a professor of bioinformatics at the ‘University of Oxford, then as Professor of Biostatistics at the University of Washington and Co-Chair of the Herbold Bioinformatics Program at the Fred Hutchinson Cancer Research Center.
Cardon received his doctorate from the University of Colorado and conducted his postdoctoral research in the Department of Mathematics at Stanford University. He has received a Principal Fellowship from the Wellcome Trust and is an elected member of the UK Academy of Medical Sciences and the American Association for the Advancement of Science.
Cardon is the author of more than 225 scientific publications and 15 books and chapters, primarily focused on genetic methodology, applications and findings for rare and common diseases, ranging from Huntington’s disease to dyslexia, according to Jackson Lab. .
“For many years, there has been an immense promise to translate the discoveries of human genetics and genomics into new diagnoses, prognoses and treatments for common and rare diseases,” Cardon said in the release. “A lot of the fundamentals are finally in place. The next step is to put them together to start fulfilling that promise. “
Foreign money is secretly flooding America’s tax havens. Part is tainted.